Geron up ACTC up and AAPL up a good day

This is from the a Yahoo Message broad:
Cancer is #1 now, buy HESC's, with a partner, are still very much in GERN's future. The company is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases.

Geron (GERN) is still a world leader in the development of human embryonic stem cell-based therapeutics, but for financial reasons, that is now taking a back seat.

Indefinite replicative capacity – indefinite proliferation to enable production of a limitless supply of cells for scalable manufacturing of products for clinical use.
Pluripotency – capacity to develop into most cell types for the potential treatment of a wide range of diseases and conditions.

HESCs serve as the starting material in the manufacture of specific functional therapeutic cell types. Cryopreserved, hESCs are thawed and expanded in their undifferentiated state to enable production of large multi-dose manufacturing lots. After the expansion stage, the undifferentiated hESCs are then treated with specific biologicals and growth factors to induce them to differentiate into specified functional cell types. Final product is cryopreserved for distribution and on-demand use at the point of care. Geron has developed new technologies and processes to support this product model.

Each therapeutic cell type derived from hESCs has multiple functional properties that cannot be mimicked by any single drug or conventional biologic, presenting a real opportunity to address significant unmet medical needs.

GRNOPC1 – Oligodendrocyte progenitors
GRNCM1 – Cardiomyocytes
GRNIC1 – Pancreatic islet cells
GRNCHND1 – Chondrocytes
GRNVAC2 – Dendritic cells.
Geron closed up 6 cent at $1.77 on just under 1 million shares. The three month avg. volume is 727,414 shares. We still need more volume but I think some thing good is coming.

ACTC closed up just a little at 0.0623 on 4.5 million shares. The three month avg. volume is 4.8 million shares. They are slowly moving forward with the Phase 1/2 trials with any more good results we should hit 12 cents. We would go high if we had the reverse split done, and the SEC lawsuit settled.

AAPL up $8.52 at $592.53 on 14.3 million shares. The three month avg. volume is 19.5 million shares.
AAPL is looking good, but I may sell a few shares before earnings, if we have more ran up.

Good luck in this rigged casino,